Weeks after launching Aeterna Zentaris castoff, Strongbridge turns around and sells rights to Novo Nordisk — at a premium
Reaching what appears to be an end to its winding journey to market, the growth hormone drug Macrilen has just found a new home in the US and Canada.
Novo Nordisk has scooped up regional rights to the asset from Strongbridge Biopharma, which bought them from Aeterna Zentaris this January for $24 million upfront and some milestones. That’s a bargain price compared to what the Danish drugmaker is offering now: $145 million, plus an equity investment worth more than $36 million as well as tiered royalties through 2027.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters